Cargando…

Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience

BACKGROUND: Relapsed/refractory high-risk neuroblastoma has a dismal prognosis. Anti-GD2-mediated chemo-immunotherapy has a notable anti-tumor activity in patients with relapsed/refractory high-risk neuroblastoma. The purpose of this study was to analyze the efficacy and safety of the combination of...

Descripción completa

Detalles Bibliográficos
Autores principales: Olgun, Nur, Cecen, Emre, Ince, Dilek, Kizmazoglu, Deniz, Baysal, Birsen, Onal, Ayse, Ozdogan, Ozhan, Guleryuz, Handan, Cetingoz, Riza, Demiral, Ayse, Olguner, Mustafa, Celik, Ahmet, Kamer, Serra, Ozer, Erdener, Altun, Zekiye, Aktas, Safiye
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9816792/
https://www.ncbi.nlm.nih.gov/pubmed/36620564
http://dx.doi.org/10.3389/fonc.2022.1041443